Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
Main objective : evaluation of progression free survival on R-GEMOX and enzastaurin, 1 year after treatment start, in patients with relapsed DLBCL or transformed (CD20+) indolent lymphoma, who are older than 60 years. Patients who are younger than 60 may be included if they are not eligible for HDC followed by ASCT
Inclusion criteria
- high-risk diffuse large B-cell lymphoma (DLBCL )